Hydroxylated Tropolones Inhibit Hepatitis B Virus Replication by Blocking Viral Ribonuclease H Activity

作者：Lu, Gaofeng; Lomonosova, Elena; Cheng, Xiaohong; Moran, Eileen A.; Meyers, Marvin J.; Le Grice, Stuart F. J.; Thomas, Craig J.; Jiang, Jian-kang; Meck, Christine; Hirsch, Danielle R.; D'Erasmo, Michael P.; Suyabatmaz, Duygu M.; Murelli, Ryan P.; Tavis, John E.^*

来源：Antimicrobial Agents and Chemotherapy, 2015, 59(2): 1070-1079.

DOI：10.1128/AAC.04617-14

• HIV-1 REVERSE-TRANSCRIPTASE
• LONG-TERM EFFICACY
• RNASE-H
• ALPHA-HYDROXYTROPOLONES
• NATURAL-HISTORY
• DNA
• INTEGRASE
• SITE
• EPIDEMIOLOGY
• SUPERFAMILY

Hepatitis B virus (HBV) remains a major human pathogen despite the development of both antiviral drugs and a vaccine, in part because the current therapies do not suppress HBV replication far enough to eradicate the virus. Here, we screened 51 troponoid compounds for their ability to suppress HBV RNaseH activity and HBV replication based on the activities of alpha-hydroxytropolones against HIV RNaseH, with the goal of determining whether the tropolone pharmacophore may be a promising scaffold for anti-HBV drug development. Thirteen compounds inhibited HBV RNaseH, with the best 50% inhibitory concentration (IC50) being 2.3 mu M. Similar inhibition patterns were observed against HBV genotype D and C RNaseHs, implying limited genotype specificity. Six of 10 compounds tested against HBV replication in culture suppressed replication via blocking of viral RNaseH activity, with the best 50% effective concentration (EC50) being 0.34 mu M. Eighteen compounds inhibited recombinant human RNaseH1, and moderate cytotoxicity was observed for all compounds (50% cytotoxic concentration [CC50] = 25 to 79 mu M). Therapeutic indexes ranged from 3.8 to 94. Efficient inhibition required an intact alpha-hydroxytropolone moiety plus one or more short appendages on the tropolone ring, but a wide variety of constituents were permissible. These data indicate that troponoids and specifically alpha-hydroxytropolones are promising lead candidates for development as anti-HBV drugs, providing that toxicity can be minimized. Potential anti-RNaseH drugs are envisioned to be employed in combination with the existing nucleos(t) ide analogs to suppress HBV replication far enough to block genomic maintenance, with the goal of eradicating infection.

• 出版日期2015-2
• 单位郑州大学